Laboratory Diagnosis of Clostridium Difficile in the Republic of Ireland: a Survey of Irish Microbiology Laboratories. by Drudy, Denise et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles School of Biological Sciences 
2008 
Laboratory Diagnosis of Clostridium Difficile in the Republic of 
Ireland: a Survey of Irish Microbiology Laboratories. 
Denise Drudy 
Technological University Dublin, denise.drudy@tudublin.ie 
F. Fitzpatrick 
Beaumont Hospital, Dublin 
A. Oza 
Health Protection Surveillance Centre, Dublin, Ireland 
A. Gilleece 
Connolly Hospital, Dublin, Ireland 
A. M. O’Byrne 
Health Services Executive e Southeast, Ireland 
Follow this and additional works at: https://arrow.tudublin.ie/scschbioart 
 Part of the Biology Commons 
Recommended Citation 
Drudy, D. et al (2008) Laboratory Diagnosis of Clostridium difficile in the Republic of Ireland: a survey of 
Irish microbiology laboratories, Journal of Hospital Infection vol. 68,pp.315-321 . doi:10.1016/
j.jhin.2008.01.025. 
This Article is brought to you for free and open access by 
the School of Biological Sciences at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
Laboratory diagnosis of Clostridium difficile-
associated disease in the Republic of Ireland:
a survey of Irish microbiology laboratories
F. Fitzpatrick a,b,*, A. Oza a, A. Gilleece c, A.M. O’Byrne d, D. Drudy e,
on behalf of the C. difficile subcommittee of the Health Protection
Surveillance Centrey
a Health Protection Surveillance Centre, Dublin, Ireland
b Department of Microbiology, Beaumont Hospital, Dublin, Ireland
c Connolly Hospital, Dublin, Ireland
d Health Services Executive e Southeast, Ireland
e Centre for Food Safety, University College Dublin, Dublin, Ireland
Received 1 October 2007; accepted 21 January 2008




Summary The Health Protection Surveillance Centre (HPSC) established
a group to produce national guidelines for Clostridium difficile in Ireland
in 2006. A laboratory questionnaire was distributed to determine current
C. difficile diagnostic practices. Twenty-nine out of 44 laboratories provid-
ing C. difficile diagnostic services to 34 hospitals responded. Twenty-five
out of 29 (86%) laboratories processed specimens for C. difficile and four
(13.8%) forwarded specimens to another laboratory. Sixteen laboratories
(64%) processed specimens for other healthcare facilities. None routinely
examined stool for C. difficile, seven (28%) examined specimens only when
requested to do so and 18 (72%) used specific selection criteria, including
testing all liquid stools (39%), all nosocomial diarrhoea (44%), specific clin-
ical criteria (28%) and history of antibiotic therapy (22%). All tested stool
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directly for C. difficile toxin with a variety of enzyme immunoassays, with
24 (96%) detecting both toxin A and B and one detecting toxin A only. Three
(12%) laboratories used cytotoxicity assays; none used polymerase chain
reaction and six (24%) laboratories performed C. difficile culture but only
under specific circumstances. Seven (28%) laboratories had isolates typed
during outbreaks, but none had the facilities to do so on-site. The HPSC
group will produce national recommendations for laboratory diagnosis, sur-
veillance and management of C. difficile infection. Since there are marked
differences in diagnostic practices throughout the country and no national
reference laboratory, the implementation of these recommendations will
have cost implications that will need to be addressed.
ª 2008 The Hospital Infection Society. Published by Elsevier Ltd. All rights
reserved.
Introduction
Clostridium difficile is responsible for a spectrum
of infection ranging from asymptomatic colonisa-
tion to diarrhoea of varying severity, including
life-threatening colitis. In the Republic of Ireland,
the Health Protection Surveillance Centre (HPSC)
is responsible for the collation and analysis of
weekly notifications of infectious diseases.1 Unlike
many infectious diseases, C. difficile is not notifi-
able; therefore the extent of C. difficile infection
in the country is unclear. The only source of
national data is that from the third Hospital Infec-
tion Society (HIS) prevalence study of healthcare-
associated infections in acute hospitals in the UK
and Ireland conducted in 2006.2 Forty-four acute
hospitals in the Republic of Ireland participated
in this study, which surveyed 7541 patients. The
number of patients with current C. difficile diar-
rhoea (defined as a patient with diarrhoea which
was positive for C. difficile toxin) was recorded
for each patient. Thirty-six patients (0.5% preva-
lence) were reported as having C. difficile infec-
tion. The majority, 25/36 (69%) were aged >75
years.
Unlike sporadic cases of C. difficile infection,
outbreaks of infectious diseases have been notifi-
able in Ireland since 1 January 2004.1 Between
January 2004 and September 2007, eight out-
breaks of C. difficile infection were reported to
the HPSC, five in acute hospital settings and three
in residential institutions.3 However, unlike other
countries the number of patients involved ranged
from three to 18 patients, and with the exception
of a hospital-wide outbreak reported in the
1990s, there have been no reported large-scale
outbreaks of C. difficile in the Republic of Ire-
land.4e9
As C. difficile-associated disease (CDAD) and
particularly that associated with ribotype 027
has high epidemic potential, the European Cen-
tre for Disease Prevention and Control (ECDC)
has expressed a need for individual member
states to develop early-warning mechanisms and
to implement a patient-based surveillance sys-
tem.8 While neighbouring countries such as the
UK have introduced various systems of mandatory
and voluntary surveillance, the Republic of Ire-
land has no national information on the inci-
dence of CDAD.
In view of the paucity of information and the
clear need to establish ongoing national surveil-
lance to guide future health policies and to provide
a benchmark for future interventions, the scien-
tific advisory committee of the HPSC established
a group to produce national guidelines on the
surveillance, diagnosis and management of C.
difficile in Ireland. In order to produce recommen-
dations for standardised national surveillance of
CDAD, it is essential that laboratories use similar
testing protocols for C. difficile. As part of its
work, the group undertook a laboratory survey to
determine the current laboratory diagnostic prac-
tices for C. difficile in the Republic of Ireland.
Methods
A questionnaire was designed by the group to
evaluate all aspects of diagnostic testing and
specimen processing for C. difficile (Figure 1). It
was divided into five main sections focusing on rou-
tine laboratory diagnostic methods, use of C. diffi-
cile culture, typing of strains, specimen selection
and strategies for repeat C. difficile testing. Not
all hospitals in Ireland have a microbiology
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laboratory, therefore questionnaires were sent
only to those hospitals with such a facility. In No-
vember 2006, questionnaires were sent to 44 acute
hospital laboratories. Reminders were sent to
laboratories by e-mail and followed up by phone
call if responses were not received. The results
of the survey were collated at the HPSC and ana-
lysed with Microsoft Access.
1. Diagnostic method routinely used for C. difficile in your laboratory  
Does your laboratory  
a. Process faecal specimens for C. difficile?
Yes / No / Yes but done elsewhere
If tested elsewhere, please state where:  
If yes, please list the hospitals:  
Please specify  
Other (please provide details) 
b. Process faecal specimens for C. difficile for other hospitals? Yes / No
c. Have an SOP for processing faecal specimens for C. difficile? Yes / No
d. Test for toxin directly from stools? Yes / No
Cytotoxicity assay Yes / No
ELISA Yes / No
Toxin A only Yes / No
Toxin A and B Yes / No
PCR Yes / No
Yes / No
2. Culture of C. difficile strains
Does your laboratory culture C. difficile?  Yes / No / Yes but done elsewhere 
–    Please specify the selective medium used: 
Please specify: 
–    Selective agar Yes / No
–    Alcohol shock Yes / No
–    Alcohol shock and selective agar Yes / No
Does your laboratory confirm toxin detection on C. difficile isolates? Yes / No
–    Toxin detection from strains Yes / No
–    Cytotoxicity assay Yes / No
–    ELISA Yes / No
–    PCR Yes / No
3. Typing of C. difficile strains 
Does your laboratory type C. difficile isolates?   Yes / No / Yes but done elsewhere 
Please specify method and laboratory: 
4. Strategy for C. difficile testing (SPECIMEN SELECTION) 
[  ] Only when specifically requested 
[  ] Systematically based on the following criteria: 
 [  ] On all stool cultures sent to the laboratory 
[  ] On stools from certain departments (if so, please specify below)
 [  ] On all liquid stools 
 [  ] If antibiotic treatment is stated   
 [  ] In cases of suspected nosocomial diarrhoea 
[  ] Only on patients over a certain age (age cut-off………………)
 [  ] On outpatient community specimens 
 [  ] Other criteria, please specify: 
5.  Strategy for REPEAT C. difficile testing 
Does your laboratory have a policy on repeat testing for patients previously positive for C. 
difficile toxin?        Yes / No
[  ] Once a week  
[  ] All repeat specimens tested 
[  ] Specimens from previously positive patients are not retested for four weeks 
Figure 1 Questionnaire on diagnosis of C. difficile disease in Irish laboratories. SOP, standard operating policy;
ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction.
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Results
Questionnaires were returned from 29/44 laborato-
ries (66% response) providing C. difficile diagnostic
services to 34 hospitals. Responses were received
from 10 regional/tertiary hospital laboratories (rep-
resenting all regional/tertiary hospitals), 14 general
or private hospital laboratories and five single spe-
cialist hospitals. Non-responders were from general
or private hospital laboratories.
Specimen selection
Twenty-five out of 29 (86%) laboratories processed
specimens for C. difficile. Four (13.8%) laborat-
ories did not perform C. difficile diagnosis on-site
but forwarded specimens to an outside laboratory
for processing. Sixteen (64%) laboratories pro-
cessed specimens for other healthcare facilities
including nursing homes, general practitioners
and other hospitals.
Seven (28%) laboratories examined specimens
for C. difficile only when requested to do so and 18
(72%) used specific selection criteria for examining
specimens. These criteria included the following:
e stool consistency (seven laboratories tested all
liquid stools)
e patient age (one laboratory tested all specimens
when patients were aged >1 year)
e patient location (two laboratories tested all
stools from specific departments such as oncol-
ogy and high-dependency care units)
e antibiotic therapy (four laboratories tested
stools if the request form indicated that the pa-
tient was on antibiotics),
e clinical criteria (five laboratories)
e nosocomial diarrhoea suspected (eight
laboratories).
Policies for C. difficile testing
Of the 25 laboratories that tested specimens for C.
difficile, four (16%) did not have a standard oper-
ating policy for C. difficile testing. Twenty (80%)
had a policy for repeat testing, although these pol-
icies varied greatly: this included testing repeat
specimens weekly (two laboratories), testing all
repeat specimens (five laboratories) or not retest-
ing specimens from previously positive patients for
four weeks after the last positive specimen (four
laboratories). The remaining nine laboratories
retested specimens after two weeks, 10 days or
decided either on an individual basis or after dis-
cussion with the consultant microbiologist.
Routine C. difficile diagnostic methods
Twenty-five laboratories that tested specimens for
C. difficile tested for C. difficile toxin (Table I).
Twenty-four (96%) hospitals used enzyme immuno-
assays (EIAs) that detect both toxin A and B. Just
one hospital used an assay that detected toxin A
only. Twenty-three laboratories provided details of
the EIA used to detect C. difficile toxin (Table I).
In addition, three laboratories used a cytotoxicity
assay and none used polymerase chain reaction
testing for C. difficile toxin.
None of the laboratories routinely cultured all
specimens for C. difficile. Six (24%) cultured speci-
mens in specific circumstances such as during
outbreaks. Three laboratories used selective agar
and three cultured onto blood agar following
faecal alcohol shock.
C. difficile typing
Seven (28%) laboratories typed strains in the case
of an outbreak. These isolates were typed either in
the UK (two laboratories) or at University College
Dublin (three laboratories). The location of typing
was unknown for two laboratories.
Discussion
This is the first time that a survey of laboratory
methods for C. difficile diagnosis has been per-
formed in the Republic of Ireland. The majority
Table I Routine C. difficile diagnosis in 25 Irish
laboratories
Diagnostic methods No. of
laboratories




Meridian Premier Toxin Aþ B 12
Meridian Premier Immunocard Aþ B 4
Techlab Clostridium difficile Tox A/B ll 3
Combination of Meridian Premier
Toxin Aþ B & Meridian Immunocard
2
Aþ B 1
Remel Xpect Clostridium difficile
Toxin A/B Test Kit
1
VIDAS[R] C. difficile Toxin A II (CDA 2)
assay (bioMe´rieux, Inc.)
Cytotoxicity assay 3
Polymerase chain reaction 0
Culture
Routine 0
Only in specific circumstances 6
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of completed questionnaires were received from
laboratories with a consultant microbiologist and
an infection control nurse either on-site or with
a sessional commitment and represented all re-
gional/tertiary hospital laboratories and many of
the larger general hospitals. The major finding of
this survey is that there are marked differences
in C. difficile testing strategies and methodologies
between Irish laboratories. This is similar to other
countries where other surveys have been per-
formed, and underlines the need for agreed na-
tional guidelines.10e12
Twenty-five (86%) Irish laboratories performed
C. difficile diagnosis on-site and 16 (64%) pro-
cessed specimens for other hospitals. The rest for-
warded specimens to an outside laboratory for
processing. None of the laboratories routinely ex-
amined stool specimens for C. difficile, seven
(28%) examined specimens only when requested
to do so and 18 (72%) used specific selection cri-
teria. These criteria included testing all liquid
stools (39%), all stools from nosocomial diarrhoea
(44%), specific clinical criteria (28%) and history
of antibiotic therapy (22%). Notably, while 16% of
laboratories did not have a written standard
operating policy for testing stool specimens for
C. difficile, the majority (80%) had a policy for
repeat testing; however, there were marked varia-
tions in repeat testing strategies between laborat-
ories. While the numbers in this survey are smaller,
the findings are similar to those from a 2002
European survey of diagnostic methods and testing
protocols for C. difficile among 212 hospitals in
eight countries.10 In that survey, marked differ-
ences were found among laboratories with respect
to the methods and strategies used for diagnosing
CDAD. While 88% of laboratories performed C. dif-
ficile diagnosis with 40% testing all liquid speci-
mens, a higher proportion of laboratories in that
survey tested specimens if there was a history of
antibiotic therapy (45%) or nosocomial diarrhoea
(57%).10
While the issue of specimen selection is of
importance in the day-to-day management of
patients, there is surprisingly little in the litera-
ture on this topic. UK recommendations are based
on the assumption that the presence of C. difficile
toxin is only of clinical relevance in patients with
diarrhoea and that CDAD occurs rarely in children
aged <2 years. Hence the recommendation to re-
strict testing to diarrhoeal stools only; a diarrhoeal
stool being defined as one that takes up the shape
of its container. In addition, testing of children
aged <2 years is not advised.13 A recent study
evaluated this approach and supported the recom-
mendation that testing should only be performed
on stools that take up the shape of their container.
In this study, restricting testing to liquid stools only
(as opposed to ‘soft’ samples e ‘soft’ being de-
fined as diarrhoeal according to the definition
above, but not liquid) would have missed at least
54.9% of clinically significant results. Refusing to
test samples that did not take up the shape of their
container, however, did not seem to cause the di-
agnosis of CDAD to be delayed or missed.14 Other
authors also recommend that tests for C. difficile
or its toxins be done only on diarrhoeal (unformed)
stool specimens unless ileus is present.15,16 With
regard to which patients to test, in one study prior
antibiotic therapy, significant diarrhoea (defined
as new onset of more than three partially formed
or watery stools per 24 h period) and abdominal
pain were independent predictors of a positive cy-
totoxin assay result. A decision rule (defined as
positive if prior antibiotic use and either significant
diarrhoea or abdominal pain are present) that was
applied to specimens before testing demonstrated
sensitivity and specificity of 86 and 45%, leading
the authors to conclude that patients without prior
antibiotic use and either significant diarrhoea or
abdominal pain may not routinely require cyto-
toxin testing.17 One of the main disadvantages of
this approach is the reliance on accurate clinical
data being recorded on sample submission to the
laboratory, which in practice may be an unattain-
able goal. Furthermore, recent studies have de-
scribed severe cases of CDAD in patients without
traditional risk factors for CDAD including prior
hospitalisation and previous exposure to antimi-
crobials. Restricting laboratory diagnosis to pa-
tients with more than three days hospitalisation
and a history of antibiotic exposure could under-
estimate CDAD cases.18
Regarding the methods used for C. difficile
diagnosis, all laboratories used EIAs to test stool
directly for C. difficile toxin, with the majority
(96%) testing for both toxin A and B. A large variety
of EIAs were used by laboratories. In addition three
(12%) laboratories used a cytotoxicity assay. Only
six (24%) laboratories performed C. difficile cul-
ture and only in specific circumstances such as dur-
ing an outbreak. Although seven (28%) laboratories
typed strains during outbreaks, none had the facil-
ities to do so on-site. These findings differ from the
2002 European study where 55% of laboratories
were capable of culturing for C. difficile.10 Wide
variations existed among countries that partici-
pated in this study, with culture performed in
more than 90% of the laboratories in Denmark
and Belgium, but only in 28% of Spanish and 20%
of UK laboratories. Culture enables typing and an-
timicrobial susceptibility testing of C. difficile
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strains that are important from an epidemiological
perspective; typing allows clonal strains to be
traced and recognition of the emergence of spe-
cific virulent clones and an effective C. difficile
surveillance programme requires that susceptibil-
ity testing be performed on isolates so that resis-
tance rates and trends can be monitored to track
the emergence of drug resistance.19
Current UK guidelines recommend testing for C.
difficile toxin by either immunoassay or cell cyto-
toxic assay.13 The reason why adjunctive culture is
not recommended is probably linked to a combina-
tion of increased cost and a requirement for
specific technical expertise. However, these
guidelines were implemented before the increas-
ing incidence of C. difficile 027 and many of the
current EIAs in use in Irish laboratories have been
demonstrated to have poor sensitivity. Two recent
studies demonstrated sensitivity rates of 64% and
59% respectively with toxin AB EIAs.20,21 These
poor sensitivity rates may reflect the sample pop-
ulation being analysed as both hospitals processed
samples for other healthcare facilities and samples
may not have been stored optimally before trans-
portation to the testing laboratories. Other studies
have demonstrated that suboptimal storage of fae-
cal samples may have a detrimental effect on toxin
titres.22
Some authors have shown that increased yields
of positive results can be obtained by using culture
in combination with toxin assays.20,23,24 This strat-
egy, which is currently recommended in Denmark
and Belgium, has recently been demonstrated to
produce high sensitivity (>90%) and specificity
(>98%) when used to detect for CDAD.25 A survey
performed in the UK by the Healthcare Commission
and Health Protection Agency among 118 National
Health Service Trusts in 2005 revealed that little
had changed in the UK with respect to the number
of laboratories performing C. difficile culture from
their previous survey in 2002 (25% laboratories);
however, a further 20% laboratories were consider-
ing introducing culture.26 In addition, there was
considerable variation in the use of culture strat-
egies between different trusts. The extra resources
required for culture (cost and expertise) are
considered drawbacks to the introduction of
C. difficile culture in many laboratories. The intro-
duction of a repeat testing strategy where toxin-
positive patients were not retested for two weeks
would save a significant part of the C. difficile bud-
get. In addition to cost and expertise issues, the
low percentage of Irish laboratories that culture
or send strains for C. difficile typing may also be
due to the lack of a C. difficile reference labora-
tory in the Republic of Ireland. Laboratories that
wish to type strains either have to send isolates
to another country (usually to the UK) or send
them to University College Dublin where typing is
carried out as part of a research project; this is
not a routine diagnostic service.
In summary, similar to other national surveys of
C. difficile diagnosis, our survey has revealed
marked differences in testing strategies and diag-
nostic methodologies in laboratories in the Repub-
lic of Ireland. Recently, the first case of C. difficile
027 in Ireland was reported from a patient trans-
ferred from a UK hospital.27 This report also de-
scribed two clusters of C. difficile ribotype 027 in
two Irish hospitals. Since there is no national
C. difficile surveillance programme or reference
facility in Ireland and isolates are not routinely
cultured or typed, the extent of C. difficile infec-
tion in the country is unclear. Our group will pro-
duce national recommendations for laboratory
diagnosis and typing and surveillance of C. difficile
infection, including standardization of C. difficile
diagnostics. As the survey has shown marked dif-
ferences in practice throughout the country, the
implementation of these recommendations will
have cost implications that will need to be
addressed.
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